Iodixanol Pharmacokinetics in Children
dc.contributor.author | Marsters, P. A. | en_US |
dc.contributor.author | Lloyd, Thomas R. | en_US |
dc.contributor.author | Johnson, J. A. | en_US |
dc.contributor.author | Ardinger, R. H. Jr. | en_US |
dc.contributor.author | Slovis, Thomas L. | en_US |
dc.contributor.author | Zales, V. R. | en_US |
dc.contributor.author | Leff, R. D. | en_US |
dc.contributor.author | Epstein, Michael L. | en_US |
dc.contributor.author | Johnson, W. H. Jr. | en_US |
dc.contributor.author | Victorica, B. E. | en_US |
dc.date.accessioned | 2006-09-08T20:16:56Z | |
dc.date.available | 2006-09-08T20:16:56Z | |
dc.date.issued | 2001-05 | en_US |
dc.identifier.citation | Johnson, Jr., W.H.; Lloyd, T.R.; Victorica, B.E.; Zales, V.R.; Epstein, M.L.; Leff, R.D.; Ardinger, Jr., R.H.; Slovis, T.L.; Johnson, J.A.; Marsters, P.A.; (2001). "Iodixanol Pharmacokinetics in Children." Pediatric Cardiology 22(3): 223-227. <http://hdl.handle.net/2027.42/42384> | en_US |
dc.identifier.issn | 0172-0643 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42384 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11343148&dopt=citation | en_US |
dc.description.abstract | The objective of this report was to study the elimination pharmacokinetics of iodixanol in children. Iodixanol (V isipaque ®, Nycomed Inc., Wayne, PA, USA) is a new iso-osmolar iodinated radiocontrast agent. We hypothesized that elimination of this agent would be dependent on age-related differences in renal clearance. Seven centers enrolled 43 patients. Cardiac catheterization was performed in 41 patients and cranial computed tomography in 2. Patients were entered into 5 age groups: newborn to <2 months, 2 to <6 months, 6 months to <1 year, 1 to <3 years, and 3 to ≤12 years. Plasma samples were obtained before and at 4 time periods after completion of iodixanol injection: 0.75–1.25 hours, 2–4 hours, 8–12 hours, and 16–32 hours. Plasma concentrations of iodixanol were determined using high performance liquid chromatography. The primary pharmacokinetic endpoint was the terminal elimination rate constant ( k el ). Data were complete for 40 patients, showing mean k el significantly lower in newborn to <2-month-old patients vs older patients: (h −1 , mean ± standard deviation [SD]): newborn to <2 months 0.185 ± 0.060, 2 to <6 months, 0.256 ± 0.046, 6 months to <1 year 0.299 ± 0.042, 1 to <3 years 0.322 ± 0.058, and 3 to ≤12 years 0.307 ± 0.071; with increasing age, excretion is more rapid, as shown by each age group's elimination half-life ( t 1/2 β) (h) 4.14 ± 1.41, 2.79 ± 0.55, 2.36 ± 0.37, 2.23 ± 0.51, and 2.36 ± 0.52, respectively. Iodixanol has elimination in children >6 months of age that is comparable to normal adults. Prolonged elimination in children <6 months of age is related to renal immaturity. | en_US |
dc.format.extent | 103653 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag New York Inc. | en_US |
dc.subject.other | Key Words: Angiography — Contrast Media — Pharmacokinetics | en_US |
dc.subject.other | Legacy | en_US |
dc.title | Iodixanol Pharmacokinetics in Children | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, Division of Pediatric Cardiology, University of Michigan Medical Center, CS Mott Children's Hospital, Ann Arbor, MI 48109, USA, US | en_US |
dc.contributor.affiliationother | Departments of Pharmacy and Pediatrics, The University of Kansas Medical Center, Kansas City, KS 66160, USA, US | en_US |
dc.contributor.affiliationother | Department of Pediatric Imaging, Children's Hospital of Michigan, Detroit, MI 48201, USA, US | en_US |
dc.contributor.affiliationother | Nycomed Inc., Wayne, PA 19087, USA, US | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Division of Pediatric Cardiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA, US | en_US |
dc.contributor.affiliationother | Division of Pediatric Cardiology, Children's Hospital of Michigan, Detroit, MI 48201, USA, US | en_US |
dc.contributor.affiliationother | Nycomed Inc., Wayne, PA 19087, USA, US | en_US |
dc.contributor.affiliationother | The Deborah Heart and Lung Center, Browns Mills, NJ 08015, USA, US | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Division of Pediatric Cardiology, University of Florida, Gainesville, FL 32610, USA, US | en_US |
dc.contributor.affiliationother | Department of Pediatrics, LM Bargeron Division of Pediatric Cardiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 11343148 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42384/1/246-22-3-223_10220223.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002460010208 | en_US |
dc.identifier.source | Pediatric Cardiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.